Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies.

Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies.
复制标题

DOI:
10.1158/1055-9965.epi-09-0618
复制
发表时间:
2010-03
期刊:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子:
--
通讯作者:
Kraft P
Kraft P
中科院分区:
其他
文献类型:
--
作者:
Lindström S;Hunter DJ;Grönberg H;Stattin P;Wiklund F;Xu J;Chanock SJ;Hayes R;Kraft P

文献摘要

被引文献

相似文献

Toll样受体家族的两个成员TLR 4和基因簇TLR 6 -1-10的遗传变异在几项研究中与前列腺癌有关,但相关等位基因在报告中并不一致。我们进行了一项合并分析,将来自三项病例对照研究(CAPS、HPFS和PLCO)的基因型数据与来自3,101例前列腺癌病例和2,523例对照的数据相结合。我们进行插补,以获得密集的覆盖率的基因和可比的基因型数据的所有队列。在整个数据集中,总共对TLR 4中的58个SNP和TLR 6 -1-10中的96个SNP进行了基因分型或插补和分析。我们进行了队列特异性分析以及荟萃分析和汇总分析。我们还评估了分析是否因年龄或疾病严重程度而不同。我们没有观察到TLR 4和TLR 6 -1-10基因座的遗传变异与前列腺癌风险之间的总体相关性。TLR 4和TLR 6 -1-10中常见的生殖系遗传变异似乎与前列腺癌的风险没有很强的关联。
Genetic variation in two members of the Toll-like receptors family, TLR4 and the gene cluster TLR6-1-10, has been implicated in prostate cancer in several studies, but the associated alleles have not been consistent across reports. We performed a pooled analysis combining genotype data from three case-control studies, CAPS, HPFS and PLCO, with data from 3,101 prostate cancer cases and 2,523 controls. We performed imputation to obtain dense coverage of the genes and comparable genotype data for all cohorts. In total, 58 SNPs in TLR4 and 96 SNPs in TLR6-1-10 were genotyped or imputed and analyzed in the entire dataset. We performed cohort-specific analysis as well as meta-analysis and pooled analysis. We also evaluated whether the analyses differed by age or disease severity. We observed no overall association between genetic variation at the TLR4 and TLR6-1-10 loci and risk of prostate cancer. Common germline genetic variation in TLR4 and TLR6-1-10 does not appear to have a strong association with risk of prostate cancer.